NASDAQ: MLYS

Mineralys Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for MLYS. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-19 23:22 UTC.

What Mineralys Therapeutics, Inc. does

This biopharmaceutical company develops medicines targeting diseases caused by dysregulated aldosterone. Its lead product candidate, lorundrostat, is an orally administered aldosterone synthase inhibitor being developed to treat hypertension and related conditions including chronic kidney disease and obstructive sleep apnea. The company completed five clinical trials showing that lorundrostat reduces blood pressure and was well tolerated, and submitted a regulatory application in December 2025 with a target decision date in December 2026.

Summarized from Mineralys Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Charts

Charts are in the appInteractive charts for MLYS are available in Oxford Ledge.
Open MLYS in Oxford Ledge →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-10-02

2026-10-02Chief Executive OfficerSale-75,000$1.91M
2026-09-24DirectorSale-104,320$3.01M
2026-09-22Chief Commercial OfficerSale-7,438$209.1K

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

Catalys Pacific, LLC7,903,838$213.25M0.0%
RA CAPITAL MANAGEMENT, L.P.7,692,750$207.55M0.0%
BlackRock, Inc.5,887,038$158.83M+31.4%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2024-01-04Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

Mineralys Therapeutics, Inc. (MLYS) Presents at American Heart Association Hypertension Scientific Sessions 2026 - Slideshow
Seeking Alpha Feed2026-10-09
Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026
globenewswire.com2026-10-02
Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
Yahoo2026-09-24
Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)
globenewswire.com2026-06-14NEG
Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
globenewswire.com2026-06-08

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for MLYS and 5,000+ tickers.

Create a free account — keep MLYS

For your agent

GET /api/data?ticker=MLYS

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt